• PhAXA Reveals CDK4 Control of 4E-BP1 Translation

  2026-09-26

  Mitchell and colleagues developed PhAXA, a chemoproteomic approach for assigning kinases to specific phosphorylation sites, and used it to identify CDK4-mediated phosphorylation of the translational regulator 4E-BP1. Their findings connect CDK4/6 and mTORC1 inhibitor responses to cap-dependent translation and c-Myc expression, offering a mechanistic explanation for one route of persistent translation in breast cancer cell models.

• Dabigatran Etexilate: Designing Better Thrombin Assays

  2026-09-25

  Dabigatran etexilate is a direct thrombin inhibitor research tool whose effects can look different across biochemical, plasma, and platelet assays. This guide explains how to choose endpoints, interpret prodrug-related variables, and design experiments that distinguish target engagement from downstream coagulation effects.

• SAG Protects Frataxin-Deficient Astrocytes

  2026-09-25

  Vicente-Acosta et al. report that pharmacological Hedgehog pathway activation with SAG limits mitochondrial and inflammatory abnormalities in frataxin-depleted human astrocytes. Conditioned-medium experiments further connect these astrocyte changes to impaired neuronal survival and structure, suggesting a glia-focused avenue for Friedreich’s ataxia research that still requires validation beyond cultured cells.

• CHI3L1-IN-5: Astrocyte Rescue Workflows

  2026-09-24

  Use CHI3L1-IN-5 (Compound Z17) to test whether CHI3L1 blockade can connect reduced inflammatory signaling with restored astrocyte amyloid handling. This workflow pairs NF-κB readouts with Aβ uptake and lysosomal assays, while separating study-supported findings from practical starting conditions that require optimization.

• 10058-F4: c-Myc-Max Inhibition Workflows

  2026-09-24

  Use 10058-F4 to test how c-Myc:MAX dimerization shapes transcription, cell fate, and TERT regulation—not just tumor-cell viability. This workflow guide connects practical dosing and assay controls with emerging human stem-cell findings, while distinguishing established product data from exploratory recommendations.

• Annexin-V Maps Cardiomyocyte Death After Cardiac I/R

  2026-09-23

  In a mouse model of myocardial ischemia and reperfusion, Dumont and colleagues used labeled recombinant annexin-V to detect phosphatidylserine exposure in cardiomyocytes in situ and chart its early time course. The findings show how this readout can complement DNA-fragmentation assays and help evaluate cell-death interventions, while not establishing a role for MLCK inhibition in the reported experiments.

• Jasplakinolide Actin Research Workflows

  2026-09-23

  Jasplakinolide combines membrane access with high-affinity F-actin stabilization, making it useful for controlled cytoskeletal perturbation, imaging, and cytotoxicity studies. This practical guide covers assay design, dosing logic, cross-domain chemical-genetics lessons, and troubleshooting for more reproducible results.

• G-Quadruplexes Modulate TDP-43 Toxicity

  2026-09-22

  Oldani et al. show that RNA and DNA G-quadruplexes can alter TDP-43 aggregation, stress-associated condensation, cellular distribution, and toxicity across biochemical and cellular models. The findings position G-quadruplex population and stability as a potential regulatory layer in protein-misfolding diseases, while also defining important limits for translating DNA G-quadruplex ligands into TDP-43 research.

• Cytochalasin D for Actin-Dependent Uptake

  2026-09-22

  Cytochalasin D provides a practical perturbation tool for testing whether actin remodeling controls nanoparticle uptake, epithelial barrier interactions, and cell-state changes. This workflow combines a mucosa-aware corneal model with viability controls, dose optimization, and translational safeguards for cancer and viral studies.

• Aneugen Mechanism Profiling in TK6 Cells

  2026-09-21

  The reference study presents a tiered flow-cytometric strategy for distinguishing tubulin destabilization, tubulin stabilization, and mitotic kinase inhibition as causes of chemical-induced aneugenicity. Its combination of fluorescent Taxol response, phospho-histone H3, Ki-67, and machine learning provides a practical framework for moving from genotoxicity detection toward molecular-mechanism assignment.

• Cytochalasin D in Ocular Uptake Assays

  2026-09-21

  Cytochalasin D can function as a causal probe for actin-dependent nanoparticle uptake in corneal epithelial models. This article explains how to separate cytoskeletal transport effects from toxicity, cell-cycle changes, and formulation variables using evidence from a recent ocular drug-delivery study.

• Thioguanine Assay Guide: 5 Lab Scenarios

  2026-09-20

  A scenario-based guide to using Thioguanine (SKU A4176) in viability, proliferation, cytotoxicity, and antiviral workflows. It connects reported potency data with practical decisions about solubility, controls, interpretation, and supplier reliability.

• AR Dimer-Interface Antagonists for Drug-Resistant PCa

  2026-09-19

  The reference study reports a new series of N-(1,2,4-thiadiazol-5-yl)benzo[b]oxepine-4-carboxamides that target the androgen receptor dimer interface rather than its mutation-prone ligand-binding pocket. Lead compound Y5 combined AR dimerization disruption with ubiquitin–proteasome-mediated AR degradation, retained activity against resistant AR variants, and suppressed LNCaP xenograft growth after oral administration.

• Jasplakinolide Workflows for Actin Research

  2026-09-18

  Jasplakinolide combines membrane permeability, potent actin polymerization, and filament stabilization for live-cell imaging, cytotoxicity, and fungal-growth studies. This practical guide translates its biochemical profile into controlled workflows, assay choices, and troubleshooting strategies while separating established evidence from optimization recommendations.

• Nitrocefin: Reliable β-Lactamase Assays

  2026-09-18

  Learn how Nitrocefin (SKU B6052), a chromogenic cephalosporin substrate, supports practical β-lactamase activity measurement alongside viability and cytotoxicity workflows. This scenario-based guide covers assay design, solvent compatibility, data interpretation, protocol optimization, and vendor selection.

763 records 3/51 page Previous Next 12345 下5页 Last page